On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

Middle-aged adults with long-term fluctuations in blood pressure may face a higher risk for sudden cardiac death than their ...

Both the nasal and IV forms of bumetanide had a variability in absorption of 27%, suggesting a more stable route of dosing ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Ablation is a minimally invasive procedure to treat abnormal electrical short circuits caused by a heart attack. These ...

In patients who could not afford new devices on their own, use of so-called "reconditioned" pacemakers met criteria for ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

A debate over a proposal to allow cannabis lounges in the city of Sacramento resumes this week, with council members set to ...

Treatment with the Type 2 diabetes medication metformin, lifestyle changes, or a combination of both did not improve atrial ...